Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ:NLTX) announced it will report its second quarter 2022 financial results on August 9, 2022, following the market's close. A conference call and live audio webcast will be held at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Participants can join via toll-free number (800) 715-9871 with conference ID 4116795. The archived audio will be available for replay on their Investor Relations website shortly after the event.

Neoleukin focuses on developing advanced immunotherapies for cancer and autoimmunity using innovative de novo protein design.

Positive

• Upcoming financial results announcement may indicate growth and insights into future outlook.
• Lead product candidate NL-201 is designed to offer improved tolerability and efficacy.

Negative

• None.

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

Date: Tuesday, August 9, 2022

Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern

Toll-free: (800) 715-9871

Conference ID: 4116795

Webcast URL: http://investor.neoleukin.com/events

The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

When will Neoleukin Therapeutics report its second quarter 2022 financial results?

Neoleukin Therapeutics will report its second quarter 2022 financial results on August 9, 2022.

What time is the Neoleukin Therapeutics conference call scheduled for?

The conference call is scheduled for 1:30 p.m. Pacific / 4:30 p.m. Eastern on August 9, 2022.

How can I access the Neoleukin Therapeutics earnings call?

The earnings call can be accessed by dialing toll-free (800) 715-9871 and entering conference ID 4116795.

What is the main focus of Neoleukin Therapeutics?

Neoleukin Therapeutics focuses on creating next-generation immunotherapies for cancer, inflammation, and autoimmunity.

What is NL-201 and what is its intended benefit?

NL-201 is Neoleukin's lead product candidate designed to enhance tolerability and activity as a combined IL-2 and IL-15 agonist.